Focus: Eurofarma is a Brazil-based generics and small-molecule manufacturer focused on immunology, ophthalmology, and cardiovascular therapeutics. The company operates primarily in Latin America with a portfolio concentrated in corticosteroid-based products.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Eurofarma Laboratórios to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Revenue anchor representing 47% of company portfolio; established post-loss-of-exclusivity product maintaining market share.
Help build intelligence for Eurofarma Laboratórios
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eurofarma Laboratórios's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue contributor approaching patent cliff in January 2028; represents material revenue at risk with no pipeline mitigation evident.
Niche ophthalmology/dermatology product contributing modestly to revenue; lifecycle stage unclear but tied to fluocinolone IP.
Portfolio of generic and authorized-generic fluocinolone products reinforcing company focus on single-molecule exploitation across formulations.
23 discontinued, 18 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo